Citigroup maintains SpyGlass Pharma at Buy, raises price target to $45 from $42
Citigroup kept its Buy rating on SpyGlass Pharma and increased its price target to $45 from $42, suggesting a 36.9% upside from the Nov 13 close of $32.88.
How this was made

The 30-second read
Why it matters
The rating lift could trigger short covering and buying interest.
Market read
Analyst upgrade provides a fresh catalyst for SGPH, potentially driving short‑term price appreciation.
What to watch
The upgrade does not reflect any new clinical data; it may be based on broader market sentiment.
Background
SpyGlass Pharma is a micro‑cap biotech whose stock trades around $33.
Market effects
Positive signal for small‑cap biotech sector as analysts raise expectations.
Limited to US biotech investors.
Minimal global impact.
Counterpoint
Some investors may wait for actual earnings data before acting on an analyst target.
Key entities
- AnalystCitigroup
Upgraded SpyGlass Pharma to Buy and raised price target.
